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Abstract
Background: The currently recommended treatment algorithm for patients with advanced renal cell carcinoma
who fail the first-line targeted therapy does not normally include pazopanib as a second-line treatment option. It
would therefore be of interest to determine the efficiency of pazopanib in this setting in terms of the partial
response rate (PRR), disease control rate (DCR), and progression-free survival (PFS).
Methods: Peer-reviewed clinical reports without language restriction, both full papers and conference abstracts,
which assessed the second-line use of pazopanib following failure of first-line non-cytokine-targeted therapy, were
included. After the literature retrieval, we conducted a Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA)-compliant systematic review of the literature and meta-analysis of the size of the effect
of each outcome measure (PRR, DCR, and PFS). The effect size and 95 % confidence interval (CI) were calculated
using fixed-effect or random-effects models based on the heterogeneity represented by I2 of selected studies.
Meta-analysis forest plots with a fixed-effect model showing the PRR and DCR were created.
Results: Our results show that there are no available comparative studies on pazopanib second-line treatment.
Only phase II trials or retrospective analysis reports were retrievable. Six studies (comprising 217 patients) were
included in the qualitative and quantitative analysis. Pazopanib as a second-line treatment resulted in a PRR of
23 % (95 % CI, 17–31 %; I2 = 52.6 %) and a DCR of 73 % (95 % CI, 65–80 %; I2 = 0.00 %). The meta-analysis with
fixed-effect model revealed that PFS was 6.5 months (95 % CI, 5.6–7.5 months; I2 = 86.2 %).
Conclusions: In conclusion, the effectiveness and indication of pazopanib for use in the second-line setting has
not yet been examined in-depth; however, this meta-analysis has shown that the treatment effects in terms of
PRR, DCR, and PFS may be similar to other well-studied second-line targeted therapies. Rigorous comparative
phase III trials testing this hypothesis are required.
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Background
Before the advent of targeted therapies, patients with
advanced renal cell carcinoma (RCC) were treated with
cytokine immunotherapy using interferon or interleukin-
2. Although some long-term remission was achieved,
most patients did not benefit from this treatment, but
instead suffered from significant adverse effects from the
immunotherapy. Health-related quality of life has been
shown to be significantly poorer in patients receiving
immunotherapy [1].
Up until early September 2015, at least seven targeted
agents (sunitinib, sorafenib, pazopanib, axitinib, evero-
limus, temsirolimus, and bevacizumab) have been ap-
proved for treatment of metastatic RCC (mRCC) by
the US Food and Drug Administration (FDA) [2]. In
late August 2015, the FDA granted the use of lenvati-
nib, a multiple tyrosine kinase inhibitor, for investiga-
tional use only in patients with advanced or mRCC
who had failed or did not tolerate the first-line tar-
geted therapy [3]. Non-cytokine targeted therapy has
become the first-line choice because of its favorable
toxicity profiles and ease of administration in ambula-
tory settings. Based on limited evidence from clinical
trials, expert opinions, and consensus meetings, prac-
tice guidelines on how to select these agents in se-
quential order and in defined risk groups have been
established [4]. The rationale behind the sequential
monotherapy for mRCC is mainly driven by research
results from well-designed clinical trials. Treatment
with combination therapeutics has been deemed to be
unfeasible due to toxicity profiles, or has not been
shown to be more effective than sequential monother-
apy. Several population-based studies have demon-
strated that sequential targeted monotherapy improves
overall survival [5–7]. Nevertheless, the optimal se-
quencing of targeted agents to treat mRCC and
maximize the patients’ survival is still under rigorous
investigations [8, 9].
Pazopanib was approved by the FDA in 2009 for
treatment-naïve or cytokine-failed patients with advanced
RCC. Pazopanib is an oral agent that inhibits vascular
endothelial growth factor (VEGF), PDGF, and C-Kit
tyrosine kinase receptors. However, pazopanib as a
second-line treatment for advanced RCC that is non-
responsive to previous treatment with VEGF-targeted
drugs has not received adequate investigation, and has
never proceeded to phase III trials.
The present study involved a systematic review of the
current literature with the aim of providing a more pre-
cise estimate of the treatment effects, such as the par-
tial response rate (PRR), disease control rate (DCR),
and progression-free survival (PFS) of pazopanib used
in the second-line setting after a non-cytokine VEGF-
targeted therapy.
Methods
This systematic review and meta-analysis of treatment
effect is reported according to the preferred reporting
items for systematic reviews and meta-analyses (PRISMA)
guidelines [10]. The research was performed in accord-
ance with the Declaration of Helsinki after approval by the
Kuang Tien General Hospital accredited in-house institu-
tional review board (certificate no. KTGH-10431).
Eligibility criteria
Peer-reviewed clinical reports without language restric-
tion- either full papers or conference abstracts- assessing
the second-line use of pazopanib after failed first-line
non-cytokine-targeted therapy were included. An explicit
statement of questions being addressed with reference to
participants, interventions, comparisons, outcomes, and
study design (PICOS) was established as follows: P- patients
with metastatic or advanced RCC failing first-line non-
cytokine targeted therapy; I- pazopanib as the second-line
drug; C- placebo or other antineoplastic agent when re-
garding comparative trials; O- response rate, DCR, PFS,
and overall survival (OS); S- phase III or phase II compara-
tive or non-comparative trials and retrospective analyses
would all qualify for review. Inclusion criteria were studies
reporting the treatment effect in terms of response rate,
DCR, PFS and/or OS, with a starting dose of pazopanib of
800 mg per day. Studies involving pure cytokine treatment
prior to pazopanib treatment were excluded from the
analysis.
Search methods
Full electronic searches were performed in the PubMed
biomedical literature database using medical subject head-
ings (MeSH), a controlled vocabulary thesaurus and Bool-
ean logic operators. The search phrase was (((“Carcinoma,
Renal Cell”[Mesh]) AND pazopanib)) AND ((second-line)
OR sequential OR (second line)E). Additional searches
were carried out in the EMBASE database using the
search terms: “pazopanib AND second AND line AND
renal AND cell AND carcinoma AND ([article]/lim OR
[article in press]/lim OR [conference abstract]/lim OR
[conference paper]/lim OR [conference review]/lim OR
[editorial]/lim OR [letter]/lim) AND [humans]/lim AND
[embase]/lim.” Conference abstracts published in the an-
nual meeting of the American Society of Clinical Oncol-
ogy (ASCO) and that of the European Society for Medical
Oncology (ESMO) are included in the EMBASE database.
The date of the last search was 20 May 2015.
Study selection
Duplicate records from searches of both databases were
excluded. The remaining records were screened by title
and abstract content for suitability of inclusion for further
analysis. Although potentially confirming the existence of
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unpublished studies, abstracts were excluded if they did not
contain enough information for this systematic review.
Data extraction
The name of the first author, year of publication, study
setting (phase II or retrospective), number of individuals
in the study, proportion of male patients, median age
with range, histology type of RCC, status of previous
nephrectomy, 3-tier risk category such as Memorial
Sloan-Kettering Cancer Center (MSKCC) risk group,
Motzer, Heng, or International Metastatic RCC Database
Consortium (IMDC) risk category; the first-line agent used,
complete response rate, partial response rate (PRR), DCR,
and PFS time were recorded. Mean age and standard devi-
ation data were calculated when missing [11].
PFS was defined as the time from the initiation of
pazopanib treatment to the date of documented progressive
disease (PD) based on the Response Evaluation Criteria in
Solid Tumors (RECIST) 1.0 or 1.1 criteria or death from
any cause. DCR was defined as the proportion of patients
who obtained an objective tumor response [complete re-
sponse (CR) or partial response (PR)] or those who had
achieved stable disease (SD) based on RECIST version 1.0
or version 1.1 criteria. Both older and newer versions of
RECIST criteria have been widely accepted for objectively
assessing responses to therapy in patients with RCC treated
with targeted therapy. In a recent study investigating the
concordance between RECIST 1.1 and RECIST 1.0 in
patients with advanced RCC receiving VEGR-targeted ther-
apy, Krajewski, K. M. et al. reported that response assess-
ments were, overall, highly concordant between the two
criteria and there was no evidence of a difference in time–
to-progression (TTP) between the two criteria [12].
Data synthesis and statistical analysis
Measuring the treatment effect
To improve the precision and the generalizability of the es-
timated treatment effect, data synthesis from selected stud-
ies using meta-analysis was planned. Studies were weighted
before pooling. The meta-analysis forest plot using the
fixed-effect model was used at the outset to calculate the
rate of partial remission and DCR with 95 % confidence in-
tervals (CI). The fixed-effect model was adopted based
upon the assumption that all of the studies to be examined
as a whole were considered to have been conducted under
similar conditions (second-line treatment following failure
of non-cytokine first-line treatment) with similar subjects
(advanced/metastatic RCC); in other words, the only differ-
ence between the selected studies was their effectiveness in
detecting the outcome of interest.
Heterogeneity analysis
Heterogeneity analysis refers to the analysis of the vari-
ation in study outcomes between studies selected for the
meta-analysis. Non-combinability testing for measuring
heterogeneity in meta-analysis was presented using I2
(=100 % x (Q-df)/Q) [13]. I2 is an intuitive and simple
expression of the inconsistency across studies and its
confidence interval is constructed using the test-based
method of Higgins and Thompson. An I2 value ≤ 24 %
was considered as having minimal heterogeneity. An I2
value between 25 and 49 % was regarded as having low
heterogeneity; an I2 value between 50 and 74 % had
moderate heterogeneity, and an I2 value ≥ 75 % was
regarded as having high heterogeneity. If the I2-value
was ≥50 %, the random-effects model was used. The
statistical software StatsDirect (StatsDirect Ltd, England)
and Comprehensive Meta-Analysis software were used
to generate the summary figures and pooled effect sizes
and CI used in the meta-analysis.
Results
A total of 60 studies were identified from the PubMed
(N = 45) and EMBASE (N = 15) databases. After removing
duplicates, 51 retrieved records were screened according to
the title and abstract for further eligibility, which subse-
quently excluded 41 records that did not qualify. The
remaining 10 records were then assessed in detail accord-
ing to the full-text with regard to eligibility for further
qualitative and quantitative synthesis, which subsequently
excluded four reports; thus, six studies were eventually
considered to be eligible for the meta-analysis (Fig. 1). Mo-
tives for exclusion included pazopanib being used beyond
second-line treatment, cytokine pretreatment, systematic
review article reporting secondary results, and missing
data. Figure 1 displays the PRISMA flow diagram for study
selection and consists of four consecutive steps from iden-
tification in databases, screening the records, checking eli-
gibility against the criteria for inclusion, and the final
inclusion step.
There were no phase IIb or III comparative clinical trials
testing pazopanib in the second-line treatment for mRCC.
Six records, of which five were journal articles and one was
a conference abstract, were retrieved for analysis [14–19].
All the non-comparative studies were published between
2013 and 2015. Only phase II trial data (N = 140), case-
series, and registry data were retrievable. The total number
of patients in these six studies was 217; 156 of patients,
from four studies, were included for meta-analysis of the
PRR, 154 from three studies for meta-analysis of the disease
control rate, and 203 from five studies were included for
the meta-analysis of PFS (Table 1).
Information on patient age was retrievable in five out
of the six studies (Table 1). Meta-analysis for mean age
with the random-effects model [11] revealed that the
mean age was 62 years (95 % CI, 60–64; range, 40–85
years). Overall, there were more male patients (range,
61–76 %). Sunitinib was used as a first-line treatment in
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187 patients and bevacizumab in 16 patients. Overall re-
sponse rates (CR + PR) to the first-line targeted therapy
have been reported in four studies showing a rate from
16 to 33 %, with an average of 23 % [14, 15, 17, 19].
None of the patients achieved a complete response
from second-line pazopanib treatment. Figure 2 displays
a meta-analysis forest plot with a fixed-effect model of
the PRR as the best response obtained after pazopanib
used as the second-line agent. A total of four studies
(comprising 156 patients) explicitly presented this rate
[14, 15, 17, 19]. The reported PRR in these four studies
ranged from 15.3 to 42.9 %. The fixed-effect model de-
rived an estimated PRR of 23 % (95 % CI, 17–31 %). A
heterogeneity test with I2 was 52.6 %, indicating the ex-
istence of a moderate degree of inconsistency across the
studies. With the random-effects model, an estimated
PRR would be 24.5 % (95 % CI, 14.5–38.4 %).
Pazopanib as a second-line treatment showed a DCR of
73 % (95 % CI, 65–80 %; I2 = 0.00 %). Three studies re-
ported the DCR with point estimates ranging from 70.6 to
77 % in a pool of 154 patients (Fig. 3) [15, 17, 19].
In the meta-analysis with a fixed-effect model for studies
on PFS that pooled five studies- containing 203 patients-
revealed a PFS of 6.3 months (95 % CI, 5.4–7.2 months;
I2 = 83.7 %). With a relatively high degree of heterogen-
eity, a random-effects model was adopted, which
showed a PFS of 7.6 months (95 % CI, 5.0–10.1 months)
(Table 2).
Discussion
Pazopanib as a second-line therapy after a non-cytokine
targeted therapy in patients with mRCC has not been
thoroughly evaluated. Oncologists who wish to prescribe
pazopanib in the second-line setting after previous use
of a targeted agent would therefore be unable to find ad-
equate information regarding the treatment effects of
pazopanib. This meta-analysis of a total of 217 patients
worldwide found a PRR of 23 % (95 % CI, 17–31 %), a
DCR of 73 % (95 % CI, 65–80 %), and a PFS time of
6.3 months (5.4–7.2 months).
In two recent phase III trials, axitinib therapy (5 mg
twice daily), when compared with sorafenib (400 mg
twice daily) as the second-line treatment in patients with
metastatic clear-cell RCC, resulted in a PFS of
8.3 months (95 % CI, 6.7–9.2) in a population of
globally-recruited patients (with 35 % of the patients
Fig. 1 The PRISMA consort flow diagram showing the process of study selection
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Table 1 Selected studies pooling 205 patients for systematic review and meta-analysis and display of main patient characteristics
First author Year
publ.




Clear cell type, % Previous nephrectomy Poor risk percent First-line targeted therapy PRR DCR PFS
(months)
Xie 2015 Phase II 85 72 % 63 (41–85) 100 % 81 % 24.4 %a sunitinib 15.3 % (11.2–23.9 %) 70.6 % 5.6 (4.1–6.7)
Hainsworth 2013 Phase II 55 76 % 60 (41–82) 100 % 89 % 29 %b sunitinib (N = 39) or
bevacizumab (N = 16)
27 % (?-?) 76 % 7.5 (5.4–9.4)
Sanchez 2013 Retrospective 32 65 % NA 81 % 74 % 28.3 %c sunitinib NA NA 13 (9.0–17.0)
Matrana 2013 Retrospective 17 69 % 65 (45–83) 100 % 89 % 34 % (MSKCC) sunitinib NA NA 3.5 (1.0–15.5)
Rautiola 2013 Retrospective 14 61 % 65 (40–82) 90 % 90 % 19 %c sunitinib 43 % 77 % 11 (4.6–15.6)
Al-Marrawi 2013 Retrospective 14 NA 50 (44–78) 92 % 90 % 17 %c VEGF inhibitord 0 % (0/2)e NA NA
DCR disease control rate, mo months, MSKCC Memorial Sloan Kettering Cancer Center risk category, NA data not available, N number of patients, PFS progression-free survival, PRR partial response rate
aInternational Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model
bMotzer risk category
cHeng risk category
dEither one of sunitinib, sorafenib, or bevacizumab













failing to respond to first-line cytokine therapy); [20]
and 6.5 months (95 % CI, 4.7–9.1) in all Asian patients
(with up to 51 % of the patients failing to respond to
first-line cytokine therapy) [21]. Sorafenib in these two
trials gave a PFS of 5.7 months (95 % CI, 4.7–6.5) for
globally-recruited patients and 4.8 months (95 % CI,
3.0–6.5) in the Asian-only population. In the Asian trial,
the overall response rate was reported as 23.7 % (17–
32 %), which is very similar to the current meta-analysis
result [21].
PRR and PFS data for second-line non-pazopanib tar-
geted agents following non-cytokine first-line therapy
are available from the recently reported SWITCH study
(only 3 % of all patients previously received cytokine
treatment) [8]. The SWITCH study is a European multi-
center, randomized phase III trial assessing sorafenib
(first-line)-sunitinib (second-line) vs. sunitinib-sorafenib
(i.e. in the reverse sequence) in patients with mRCC of
MSKCC favorable and intermediate risk. The overall re-
sponse rate in the second-line setting was 17 % in the
sorafenib-sunitinib arm and 6.6 % in the sunitinib-
sorafenib arm. The magnitude of the ORR is nearly
halved compared to the ORR attained in the first-line
targeted therapy, which was, on average 23 %, as previ-
ously mentioned. The DCR in the second-line setting
regarding the sorafenib-sunitinib arm was 49 %, whereas
the DCR in the sunitinib-sorafenib arm was 32 %. The
PFS in the second-line setting was 5.4 months (95 % CI,
3.0–5.5 months) in the sorafenib-sunitinib sequence
arm, and 2.8 months (95 % CI, 2.7–2.9 months) in the
sunitinib-sorafenib sequence arm [8].
Although direct comparison of the above-mentioned
studies with the current work is not recommended or cor-
rect, the study’s intention was to show the possible non-
inferiority of pazopanib as a second-line therapy despite
previous targeted therapy failure. Evidence-based clinical
practice guidelines such as the latest 2014 European Society
for Medical Oncology guidelines for diagnosis, treatment
and follow-up of RCC suggest pazopanib as a second-line
agent only in the setting of first-line cytokine failure [4].
Recommended second-line agents after prior targeted ther-
apy intolerance or failure do not include pazopanib, not
because of its ineffectiveness, but solely because there is
not yet enough evidence available from randomized con-
trolled trials.
What are the potential advantages when pazopanib is
chosen as a second-line drug in terms of anti-neoplastic
mechanisms and tolerability to prolonged use of pazopa-
nib? Generally, pazopanib is relatively well tolerated.
The most commonly reported treatment-related adverse
events include diarrhea (52 %, any grade), hypertension
(40 %, any grade), hair color changes (38 %, any grade),
nausea (26 %, any grade), and anorexia (24 %, any grade),
which tend to be fairly manageable [22]. An interesting
Fig. 3 Meta-analysis forest plot with a fixed-effect model showing the disease control rate (DCR), which is 73 % with a 95 % CI of 65–80 %. The total
number of individuals included in the analysis was 154. I2 = 0.000
Fig. 2 Meta-analysis forest plot with a fixed-effect model showing the partial response rate (PRR), which is 23 % with a 95 % CI of 17–31 %. The
total number of individuals included in the analysis was 156. I2 = 52.6 %. The random-effects model estimated a PRR of 24.5 % (95 % CI, 14.5–38.4 %)
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cross-over trial demonstrated that pazopanib was super-
ior to sunitinib in health-related quality of life (HRQoL)
measures, and significantly more patients reported a
preference for pazopanib over sunitinib with HRQoL
and safety as the main concerns [23].
The results of the present study could be generalized
to a subset of patients with mRCC whose mean age is
between 60 and 64 and of the clear cell type, for whom
the first-line agent was sunitinib or sorafenib. Ethnicity
and prognostic risk category are irrelevant when consider-
ing generalizability. Nevertheless, in the meta-analysis, the
proportion of patients with poor risk was only around 17 to
34 % representing a minority subgroup of the patients. At
the time of writing, we are still lacking adequate evidence-
based information on the effectiveness of each second-line
targeted agent for this particular poor-risk group.
There are several notable limitations to this study. The
number of studies available for the purposes of the
meta-analysis was limited and mostly includes small-size
studies which may lead to underpowering of the analysis.
With the exception of the meta-analysis of the DCR,
which had a negligible degree of heterogeneity (I2 =
0.000), the degree of heterogeneity of the studies was
moderate when synthesizing the PRR results, and high
in the meta-analysis of PFS. The two main reasons for
this are that three of the selected studies had fewer than
20 patients, and four of the selected studies were retro-
spective analyses, while two were phase II clinical trials.
The percentage of poor-risk patients in this cohort of
mRCC patients was 25 %, which is similar to most of
the clinical trial data with unselected patients by risk
category. It was not possible to perform subgroup meta-
analysis or stratify patients by risk group.
Poor-risk patients have very poor survival, with a median
OS of approximately 4 months following diagnosis prior to
the era of targeted therapy. With the advent of targeted
therapy, a study was performed by Heng et al., in which a
model of three risk categories incorporating the MSKCC
model with the addition of neutrophil and platelet counts
was developed and validated. In the study, the poor-risk
group (N = 152) having 3–6 prognostic factors, had a me-
dian OS of 8.8 months and a 2-year OS of 7 % [24]. The
role of pazopanib in this critical clinical scenario requires
further investigations.
Currently, having no solid data such as that derived
from a randomized controlled trial, pazopanib is not
routinely recommended for patients with advanced or
mRCC as a second-line targeted therapy after failing a
prior targeted agent out of the clinical trial setting.
Conclusion
Pazopanib as a second-line therapy for metastatic renal
cell carcinoma following therapy with a targeted agent
may be a viable option when other recommended drugs
are less suitable for a variety of reasons, such as the patient’s
inability to tolerate treatment. This meta-analysis of non-
comparative studies pooling a total of 217 patients gives a
more precise estimate of the treatment effects of pazopanib,
such as partial response rate, disease control rate, and
progression-free survival in the second-line setting.
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